Denna sida har översatts automatiskt och översättningens korrekthet kan inte garanteras. Vänligen se engelsk version för en källtext.

Clinical and Economic Effectiveness of Influenza Vaccination in Older Adults

12 november 2026 uppdaterad av: Thong Nhat Hospital

This study aims to evaluate the clinical and economic effectiveness of influenza vaccination among adults aged 60 years and older in Ho Chi Minh City, Vietnam. It will compare influenza-related health outcomes and healthcare costs between older adults who receive influenza vaccination and those who do not.

This is a prospective observational cohort study with a control group. The study plans to enroll 2,298 participants, including 766 vaccinated and 1,532 unvaccinated older adults. Participants will be recruited at Thong Nhat Hospital and University Medical Center Ho Chi Minh City. Vaccination status will be determined by participants' vaccination history and decisions made independently of the study.

Participants will be followed for 12 months, with follow-up assessments every three months. The study will collect information on influenza, influenza-like illness, cardiovascular events, respiratory events, hospitalization, mortality, and direct medical costs related to influenza.

The study will compare the occurrence of clinical outcomes and direct medical costs between the two groups. It will also evaluate economic measures related to influenza vaccination, including avoided treatment costs, cost savings, and the benefit-cost ratio. The findings will be used to provide scientific evidence for developing influenza vaccination policy recommendations for older adults in Ho Chi Minh City.

Studieöversikt

Status

Har inte rekryterat ännu

Intervention / Behandling

Detaljerad beskrivning

Participants will be recruited using consecutive convenience sampling. Baseline information will be collected using standardized data collection forms, including demographic characteristics, medical history, underlying diseases, influenza vaccination status, and other relevant clinical information.

During follow-up, data will be collected through scheduled telephone contacts, community-based follow-up, and information obtained from healthcare facilities. Reported clinical events and healthcare utilization will be verified using available medical records and other relevant sources.

To address potential differences in baseline characteristics between the vaccinated and unvaccinated groups, the study will use statistical methods to control for confounding factors. Propensity score matching will be applied to improve comparability between the two groups. The clinical and economic effectiveness of influenza vaccination will be evaluated using the collected data.

Studietyp

Observationell

Inskrivning (Beräknad)

2298

Kontakter och platser

Det här avsnittet innehåller kontaktuppgifter för dem som genomför studien och information om var denna studie genomförs.

Studiekontakt

Studera Kontakt Backup

Studieorter

    • Ho Chi Minh City
      • Ho Chi Minh City, Ho Chi Minh City, Vietnam
      • Ho Chi Minh City, Ho Chi Minh City, Vietnam
        • University Medical Center Ho Chi Minh City
        • Kontakt:
        • Kontakt:

Deltagandekriterier

Forskare letar efter personer som passar en viss beskrivning, så kallade behörighetskriterier. Några exempel på dessa kriterier är en persons allmänna hälsotillstånd eller tidigare behandlingar.

Urvalskriterier

Åldrar som är berättigade till studier

60 år och äldre (Vuxen, Äldre vuxen)

Tar emot friska volontärer

Ja

Kön som är behöriga för studier

Allt

Testmetod

Icke-sannolikhetsprov

Studera befolkning

The study population comprises adults aged 60 years or older residing in Ho Chi Minh City, Vietnam. Participants will be recruited from two cohorts: older adults receiving one dose of influenza vaccine at the vaccination centers of Thong Nhat Hospital or University Medical Center Ho Chi Minh City at enrollment, and unvaccinated older adults attending outpatient clinics at these hospitals who have not received influenza vaccination within the preceding 12 months. Participants will be selected using consecutive convenience sampling and followed for 12 months.

Beskrivning

Inclusion Criteria:

  • Adults aged 60 years or older residing in Ho Chi Minh City, Vietnam.

  • Belonging to one of the following two groups:

    • Vaccinated group: Older adults receiving one dose of influenza vaccine at the Vaccination Center of Thong Nhat Hospital or University Medical Center Ho Chi Minh City at the time of enrollment.
    • Unvaccinated control group: Older adults attending outpatient clinics at Thong Nhat Hospital or University Medical Center Ho Chi Minh City who have not received influenza vaccination within the preceding 12 months.
  • Having complete contact information and being able to be followed for 12 months through follow-up visits, telephone contact, and/or community-based follow-up.

  • Agreeing to participate in the study and providing written informed consent.

Exclusion Criteria:

  • Inability to accurately determine influenza vaccination status or the timing of influenza vaccination.
  • Refusal to participate in the study or withdrawal from the study during the prospective follow-up phase.
  • Participants in the unvaccinated control group who receive influenza vaccination during the 12-month follow-up period.

Studieplan

Det här avsnittet ger detaljer om studieplanen, inklusive hur studien är utformad och vad studien mäter.

Hur är studien utformad?

Designdetaljer

  • Observationsmodeller: COHORT
  • Tidsperspektiv: PROSPECTIVE

Kohorter och interventioner

Grupp / Kohort
Intervention / Behandling
Influenza-Vaccinated Cohort

Adults aged 60 years or older who receive influenza vaccination at the vaccination centers of Thong Nhat Hospital or University Medical Center Ho Chi Minh City during the study period. The date of vaccination serves as the start of the 12-month follow-up period.

Influenza vaccination received as part of routine healthcare, independently of the study. Vaccination is not assigned or administered by the research team as a study intervention. Participants who receive influenza vaccination are included in the vaccinated cohort and followed for 12 months.

Unvaccinated Control Cohort

Adults aged 60 years or older attending outpatient clinics at Thong Nhat Hospital or University Medical Center Ho Chi Minh City who have not received influenza vaccination during the 12 months preceding enrollment. The enrollment date serves as the start of the 12-month follow-up period.

Vad mäter studien?

Primära resultatmått

Resultatmått
Åtgärdsbeskrivning
Tidsram
Incidence of Confirmed Influenza
Tidsram: During the 12-month follow-up period

The proportion of participants with confirmed influenza during the 12-month follow-up period. Confirmed influenza is defined by a positive rapid influenza antigen test, a positive reverse transcription-polymerase chain reaction (RT-PCR) test, viral isolation, or a documented influenza diagnosis in the medical record, in accordance with the study protocol.

During the 12-month follow-up period
Incidence of Influenza-like Illness
Tidsram: During the 12-month follow-up period

The proportion of participants experiencing influenza-like illness (ILI) during the 12-month follow-up period. ILI is defined as an acute respiratory illness characterized by fever (measured body temperature of at least 38°C or self-reported fever or chills) accompanied by cough and/or sore throat, as specified in the study protocol.

During the 12-month follow-up period
Avoided Treatment Costs
Tidsram: Over the 12-month follow-up period

The estimated total treatment costs avoided through influenza vaccination over the 12-month follow-up period. Avoided treatment costs are calculated as the difference in mean treatment costs between the unvaccinated and vaccinated groups, multiplied by the number of vaccinated participants. Costs are expressed in Vietnamese dong (VND).

Over the 12-month follow-up period
Net Cost Savings
Tidsram: Over the 12-month follow-up period

Net cost savings associated with influenza vaccination over the 12-month follow-up period, calculated as the total estimated treatment costs avoided minus the total vaccination costs, in accordance with the study protocol. Net cost savings are expressed in Vietnamese dong (VND).

Over the 12-month follow-up period
Benefit-Cost Ratio
Tidsram: Over the 12-month follow-up period

The benefit-cost ratio of influenza vaccination over the 12-month follow-up period, calculated by dividing the total estimated treatment costs avoided by the total vaccination costs, as specified in the study protocol. The benefit-cost ratio is expressed as a dimensionless ratio.

Over the 12-month follow-up period

Sekundära resultatmått

Resultatmått
Åtgärdsbeskrivning
Tidsram
Incidence of Respiratory Events
Tidsram: During the 12-month follow-up period

The proportion of participants experiencing respiratory events during the 12-month follow-up period. Respiratory events include bronchitis, pneumonia, acute exacerbations of chronic obstructive pulmonary disease, and acute exacerbations of asthma, as defined in the study protocol.

During the 12-month follow-up period
Incidence of Cardiovascular Events
Tidsram: During the 12-month follow-up period

The proportion of participants experiencing cardiovascular events during the 12-month follow-up period. Cardiovascular events include acute myocardial infarction, acute stroke, and acute heart failure, as defined in the study protocol.

During the 12-month follow-up period
Incidence of Influenza-Related Hospitalization
Tidsram: During the 12-month follow-up period

The proportion of participants hospitalized during the 12-month follow-up period due to influenza, influenza-related conditions, or complications of influenza, as defined in the study protocol.

During the 12-month follow-up period
Influenza-Related Mortality
Tidsram: During the 12-month follow-up period

The proportion of participants who die during the 12-month follow-up period due to influenza, influenza-related causes, or complications of influenza, as defined in the study protocol.

During the 12-month follow-up period
Total Direct Medical Costs
Tidsram: Over the 12-month follow-up period

The total actual direct medical costs incurred during the 12-month follow-up period for the management of study-related clinical events. Costs are calculated by summing the actual medical expenditures associated with all relevant treatment episodes during follow-up and are expressed in Vietnamese dong (VND).

Over the 12-month follow-up period
Total Medical Costs Based on Health Insurance Rates
Tidsram: Over the 12-month follow-up period

The total medical costs associated with study-related clinical events during the 12-month follow-up period, calculated using the reimbursement rates specified by the Vietnamese health insurance system. Costs are summed across relevant treatment episodes and expressed in Vietnamese dong (VND).

Over the 12-month follow-up period

Samarbetspartners och utredare

Det är här du hittar personer och organisationer som är involverade i denna studie.

Utredare

  • Huvudutredare: Tan V Nguyen, PhD, Thong Nhat Hospital

Studieavstämningsdatum

Dessa datum spårar framstegen för inlämningar av studieposter och sammanfattande resultat till ClinicalTrials.gov. Studieposter och rapporterade resultat granskas av National Library of Medicine (NLM) för att säkerställa att de uppfyller specifika kvalitetskontrollstandarder innan de publiceras på den offentliga webbplatsen.

Studera stora datum

Studiestart (Beräknad)

1 januari 2027

Primärt slutförande (Beräknad)

1 maj 2028

Avslutad studie (Beräknad)

1 maj 2028

Studieregistreringsdatum

Först inskickad

12 november 2026

Först inskickad som uppfyllde QC-kriterierna

12 november 2026

Första postat (Faktisk)

18 november 2026

Uppdateringar av studier

Senaste uppdatering publicerad (Faktisk)

18 november 2026

Senaste inskickade uppdateringen som uppfyllde QC-kriterierna

12 november 2026

Senast verifierad

1 november 2026

Mer information

Termer relaterade till denna studie

Andra studie-ID-nummer

  • 26175-BVTN
  • 54/2026/HĐ-QKHCN (Annat bidrag/finansieringsnummer: Ho Chi Minh City Science and Technology Development Fund)

Plan för individuella deltagardata (IPD)

Planerar du att dela individuella deltagardata (IPD)?

OBESLUTSAM

Läkemedels- och apparatinformation, studiedokument

Studerar en amerikansk FDA-reglerad läkemedelsprodukt

Nej

Studerar en amerikansk FDA-reglerad produktprodukt

Nej

Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .

Prenumerera